NDA 019777 · Twi Pharms
Zestril
Lisinopril · Oral
Last checked: Nov 20, 2026Latest source record: Jul 21, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1988
May 19, 1988
Approved uses
5
Original approval plus efficacy supplements
Registered trials
140
25 Phase 3, 10 recruiting
FAERS reports
307,269
186,997 serious, 25,491 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue ZESTRIL as soon as possible [see Warnings and Precautions ( 5.1 )]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1)]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Zestril as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )
What it is approved for
From the label in effect Jan 2, 2025.
Zestril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Zestril is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also...
Mechanism: Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of lisinopril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to decreased aldosterone secretion....
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 1, 2003 Supplement 44 · Efficacy LetterReviewLabel
- Feb 7, 2000 Supplement 37 · Efficacy LetterReview
- Nov 24, 1995 Supplement 23 · Efficacy
- Jun 9, 1993 Supplement 7 · Efficacy
- May 19, 1988 Original approval · Type 5 - New Formulation or New Manufacturer Other Important Information from FDA
6 products under this application
- ZESTRIL · LISINOPRIL 20MG · TABLET, ORAL · Prescription · TE AB
- ZESTRIL · LISINOPRIL 5MG · TABLET, ORAL · Prescription · TE AB
- ZESTRIL · LISINOPRIL 30MG · TABLET, ORAL · Prescription · TE AB
- ZESTRIL · LISINOPRIL 40MG · TABLET, ORAL · Prescription · TE AB
- ZESTRIL · LISINOPRIL 10MG · TABLET, ORAL · Prescription · TE AB
- ZESTRIL · LISINOPRIL 2.5MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Lisinopril" as an intervention, any sponsor and status, largest first.
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of ChronotherapyPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00295542 · 3,344 participants · Start Mar 2000 · Primary completion Apr 2009
Drug: ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan) and 2 more · For: Hypertension
Sites: Santiago de Compostela, Spain
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CADPivotal-lookingActive, not recruiting
Cedars-Sinai Medical CenterAcademic, hospital or other
NCT03417388 · 2,476 participants · Start Feb 9, 2018 · Primary completion Feb 15, 2025
Drug: High dose potent statin; ACE-I (lisinopril) or ARB (losartan) and 1 more · For: Coronary Artery Disease
Sites: Mobile, Alabama; Gilbert, Arizona; Phoenix, Arizona · 81 sites in all
- Coronavirus (COVID-19) ACEi/ARB InvestigationPivotal-lookingSuspended
National University of Ireland, Galway, IrelandAcademic, hospital or other
NCT04330300 · 2,414 participants (planned) · Start Apr 30, 2020 · Primary completion Jul 31, 2021
Drug: Thiazide or Thiazide-like diuretics; Calcium Channel Blockers and 2 more · For: Hypertension; COVID-19
Sites: Galway, Ireland
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic PatientsPivotal-lookingRecruiting
Martin HuelsmannAcademic, hospital or other
NCT02817360 · 2,400 participants (planned) · Start Feb 2016 · Primary completion Dec 2025
Drug: RAS-antagonist and beta-blocker up-to maximal dosages · For: Heart Diseases; Diabetes Mellitus, Type 2
Sites: Mödling, Austria; Graz, Austria; Linz, Austria · 21 sites in all
- UMPIRE - Use of a Multidrug Pill In Reducing Cardiovascular EventsPivotal-lookingCompleted
Imperial College LondonAcademic, hospital or other
NCT01057537 · 2,004 participants · Start Jun 2010 · Primary completion Jul 2012
Drug: polypill; Usual cardiovascular medications · For: Cardiovascular Diseases
Sites: Sydney, Australia; Hyderabad, India; New Dehli, India · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue20,139
- nausea18,701
- drug ineffective17,858
- diarrhoea17,531
- dyspnoea14,122
- pain13,788
- dizziness13,716
- headache13,187
- off label use11,262
- vomiting11,193
- asthenia11,051
- arthralgia9,780
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3,531 |
| 2005 | 4,429 |
| 2006 | 4,749 |
| 2007 | 4,668 |
| 2008 | 5,695 |
| 2009 | 7,749 |
| 2010 | 10,965 |
| 2011 | 11,262 |
| 2012 | 13,038 |
| 2013 | 12,466 |
| 2014 | 17,956 |
| 2015 | 22,223 |
| 2016 | 22,908 |
| 2017 | 21,645 |
| 2018 | 23,498 |
| 2019 | 22,728 |
| 2020 | 18,102 |
| 2021 | 15,726 |
| 2022 | 15,254 |
| 2023 | 13,279 |
| 2024 | 12,698 |
| 2025 | 13,641 |
| 2026 | 9,056 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zestril (Lisinopril)
2024 spending
$3.1M
Beneficiaries
796
2,794 claims
Per beneficiary
$3,903
$12.56 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,757,754 |
| 2021 | $5,279,666 |
| 2022 | $4,881,184 |
| 2023 | $4,012,065 |
| 2024 | $3,106,440 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
· JAMA 2002 · Clinical Trial, Comparative Study
- Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis.
Hu Y, Liang L, Liu S, et al. · J Clin Hypertens (Greenwich) 2023 · Systematic Review, Network Meta-Analysis
- Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial.
Sundström J, Lind L, Nowrouzi S, et al. · JAMA 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.
Packer M, Poole-Wilson PA, Armstrong PW, et al. · Circulation 1999 · Clinical Trial, Comparative Study
- Treating Hypertension in Children With n-of-1 Trials.
Samuel JP, Tyson JE, Green C, et al. · Pediatrics 2019 · Comparative Study, Randomized Controlled Trial
- Bioequivalence evaluation of two brands of lisinopril tablets (Lisotec and Zestril) in healthy human volunteers.
Tamimi JJ, Salem II, Alam SM, et al. · Biopharm Drug Dispos 2005 · Clinical Trial, Randomized Controlled Trial
Sponsor: Twi Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.